Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00052208 · ClinicalTrials.gov registry record · Phase 1
Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 158
- Enrollment target
NCT00052208: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00052208 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 158 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00052208, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 158 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of gefitinib when given together with radiation therapy and to see how well it works in treating patients with glioblastoma multiforme. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x rays to kill tumor cells. Giving gefitinib together with radiation therapy may be an effective treatment for glioblastoma multiforme.
Interventions
- OTHER laboratory biomarker analysis
- RADIATION radiation therapy
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2002-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00052208
The ClinicalTrials.gov registry entry for NCT00052208 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00052208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00052208 about?
NCT00052208 is a clinical study titled "Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme". This phase I/II trial studies the side effects and best dose of gefitinib when given together with radiation therapy and to see how well it works in treating patients with glioblastoma multiforme. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ra...
What is the current status of trial NCT00052208?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 158 participants. The study started on 2002-03.
What interventions are being tested in trial NCT00052208?
The interventions under investigation include: laboratory biomarker analysis (OTHER), radiation therapy (RADIATION), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00052208?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.